High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer

International Journal of Gynecological Pathology

Volumn 33, Issue 4, 2014, Pages 402-410

  Davies, Suzy ^a   Holmes, Anna ^b   Lomo, Lesley ^b   Steinkamp, Mara P ^b   Kang, Huining ^a   Muller, Carolyn Y ^a   Wilson, Bridget S ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

ErbB; MET; Ovarian cancer; Tissue array

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; SCATTER FACTOR RECEPTOR; ERBB3 PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; MET PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SOLID TUMOR; TISSUE MICROARRAY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-3; RECEPTOR, ERBB-4; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902545311     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000081     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003; 13(suppl 2): 144-8.
3. Barrena Medel NI, Wright JD, Herzog TJ. Targeted therapies in epithelial ovarian cancer. J Oncol 2010 2010;314326:1-9.
4. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365: 2484-96.
6. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71.
7. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25: 5180-6.
8. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007;17:771-6.
9. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophospha-mide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
10. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61: 183-203.
11. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41.
12. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG, et al. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009;10:709-17.
13. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
14. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-23.
15. Lafky JM, Wilken JA, Baron AT, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785:232-65.
16. Yang S, Raymond-Stintz MA, Ying W, et al. Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J Cell Sci 2007;120:2763-73.
17. Gilmour LMR, Macleod KG, McCaig A, et al. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res 2001;61:2169-76.
18. Pejovic T, Pande NT, Mori M, et al. Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Transl Oncol 2009;2:341-9.
19. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met over-expression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-9.
20. Raspollini MR, Amunni G, Villanucci A, et al. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol 2006;14:181-6.
21. Peethambaram PP, Cliby WA, Lubiniecki G, et al. Her-2/neu expression in ovarian cancer: pre-and postexposure to platinum chemotherapy. Gynecol Oncol 2003;89:99-104.
22. Wong AS, Pelech SL, Woo MM, et al. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene 2001;20:1318-28.
23. Goode EL, Chenevix-Trench G, Hartmann LC, et al. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2011;20:1638-48.
24. Rubin SC, Finstad CL, Wong GY, et al. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.
25. Wong AS, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res 2002;107:161-83.
26. Zhou Y, Cashman TJ, Nevis KR, et al. Latent TGF-beta binding protein 3 identifies a second heart field in zebrafish. Nature 2011;474:645-8.
27. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-92.
28. Secord AA, Blessing JA, Armstrong DK, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:493-9.
29. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104:1241-5.
30. Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005;23: 5597-604.
31. Amler LC. HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther 2010;10:1343-55.
32. Simpson BJ, Phillips HA, Lessells AM, et al. c-erbB growth-factor- receptor proteins in ovarian tumours. Int J Cancer 1995;64:202-6.
33. Shen K, Lang J, Guo L. Overexpression of C-erbB3 in transitional cell carcinoma of the ovary. Zhonghua Fu Chan Ke Za Zhi 1995;30:658-61.
34. Simpson BJ, Weatherill J, Miller EP, et al. c-erbB-3 protein expression in ovarian tumours. Br J Cancer 1995;71:758-62.
35. Leng J, Lang J, Shen K, et al. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J 1997;12:67-70.
36. Lee CH, Huntsman DG, Cheang MC, et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 2005; 24:147-52.
37. Cancer Genome Atlas Research N. Integrated Genomic Analyses of Ovarian Carcinoma. Nature 2011;474:609-15.
38. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
39. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16:1373-83.
40. Jura N, Shan Y, Cao X, et al. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA 2009;106:21608-13.
41. Grovdal LM, Kim J, Holst MR, et al. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 2012;24:296-301.
42. Krumbach R, Schuler J, Hofmann M, et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011;47:1231-43.
43. Stamos J, Lazarus RA, Yao X, et al. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004;23:2325-35.
44. Yamamoto S, Tsuda H, Miyai K, et al. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 2011;24: 1146-55.
45. Wang MH, Padhye SS, Guin S, et al. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010;31: 1181-8.
46. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94.
47. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
48. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.